Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > More now, than before Trogarzo FDA nod

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Jan 21, 2021 10:50am

143 Views

Post# 32344554

RE:More now, than before Trogarzo FDA nod

Geez it's January and we are already talking about next year. There nothing ever right in front of us it's always couple months out, or q3, or next year. We are always saying that because management doesn't know how to provide value for shareholders

<< Previous

Bullboard Posts

Next >>

Victory Battery Metals acquires Utah and Saskatchewan uranium projects